The latest Research Excellence Framework (REF 2014) saw the School's research environment ranked as 100% world-leading or internationally excellent. The School's research output was ranked first in the Times Higher Education REF league table 2014 and 100% of the research has been internationally recognised.
The School provides a vibrant and dynamic environment for research that is ultimately directed towards the improvement of human health and patient welfare. This includes the identification and validation of new therapeutic targets, the design of biologically potent molecules, innovative new formulations for their delivery and contributions to education and health policy. Our research cuts across the traditional boundaries and is often multidisciplinary in nature.
The therapeutic areas of cancer and inflammation are a major focus within the School. We target these diseases via innovative approaches such as natural products, protein-DNA and protein-protein interactions and epigenetics to modulate specific cell signalling pathways and use our expertise in molecular pharmaceutics and nanomedicine for drug delivery.
Research in Pharmacy is funded by the BBSRC, MRC, NIHR and EPSRC national Research Councils as well as the European Union. We are funded by charities including the Association for International Cancer Research, the Leukaemia Research Fund, the Kay Kendall Research Trust, the Leverhulme Trust, Prostate Cancer UK and the Royal Society and receive industrial funding from AstraZeneca, BASF, Colorcon, Evotec, GlaxoSmithKline, Novartis and Rosemont Pharmaceuticals.